Stromectol is the original FDA‑approved brand of oral ivermectin manufactured by Merck, widely used as a systemic antiparasitic treatment. As a macrocyclic lactone, Stromectol provides reliable efficacy for scabies, strongyloidiasis, and resistant lice infestations, delivering full‑body distribution required for deep‑tissue parasitic clearance. Its branded formulation ensures consistent pharmacokinetics, high purity standards, and predictable therapeutic response across clinical settings.
While generic ivermectin tablets offer equivalent active ingredient and mechanism of action, Stromectol remains the reference standard for oral ivermectin therapy. This page provides a complete medical overview of Stromectol, including pharmacology, indications, dosing, safety, and comparison with generic formulations. Explore related sections: Ivermectin oral, Ivermectin 3 mg, Stromectol price.
Stromectol is the original brand‑name formulation of oral ivermectin, a systemic antiparasitic medication from the macrocyclic lactone class. Manufactured by Merck, Stromectol has long served as the reference standard for oral ivermectin therapy in clinical guidelines and regulatory approvals. As a prescription antiparasitic, it is used for systemic parasitic infections where full‑body distribution is required, including scabies, strongyloidiasis, and resistant lice infestations.
Stromectol is available in 3 mg and 6 mg oral tablet strengths, supporting weight‑based dosing strategies commonly used in antiparasitic treatment protocols. Although generic ivermectin tablets contain the same active ingredient and demonstrate equivalent therapeutic efficacy, Stromectol remains distinguished by its branded manufacturing standards, consistent pharmacokinetic profile, and long‑established regulatory status.
The primary differences between Stromectol and generic ivermectin relate to branding, manufacturing origin, excipient composition, and price. Generics are typically more cost‑efficient and widely available, while Stromectol carries a brand‑name premium and is often preferred in markets where brand assurance or specific regulatory approvals are valued. Despite these commercial differences, both formulations deliver the same mechanism of action: selective activation of parasite glutamate‑gated chloride channels leading to paralysis and death of target organisms.
This section provides a complete overview of Stromectol’s identity, formulation, and distinguishing characteristics, helping users understand how the branded product fits within the broader oral ivermectin therapeutic landscape.
| Parameter | Stromectol | Generic ivermectin |
|---|---|---|
| Active ingredient | Ivermectin | Ivermectin |
| Manufacturer | Merck (original brand) | Multiple manufacturers |
| Strengths | 3 mg, 6 mg | 3 mg, 6 mg |
| Bioavailability | Equivalent systemic exposure | Equivalent systemic exposure |
| Price | Higher; brand‑name premium | Lower; cost‑efficient |
| Regulatory status | Original FDA‑approved brand | Generic approvals across regions |
Stromectol, the branded oral formulation of ivermectin, acts through a highly selective neurophysiological mechanism targeting glutamate‑gated chloride channels found in invertebrate nerve and muscle cells. By binding to these channels, Stromectol increases chloride ion influx, causing hyperpolarization of parasite cells. This mechanism is unique to parasites, as humans lack these glutamate‑gated channels, which contributes to the drug’s strong safety margin. More mechanistic detail is available in Ivermectin MOA.
The resulting hyperpolarization leads to paralysis of parasites, preventing them from feeding, attaching, or reproducing. In nematodes and ectoparasites, this paralysis is irreversible, ultimately leading to death. Stromectol’s rapid onset of action makes it effective for systemic parasitic infections where immediate reduction of parasite activity is clinically beneficial.
As an oral systemic medication, Stromectol distributes throughout the bloodstream and peripheral tissues, reaching parasites located beyond the skin surface. This systemic exposure differentiates Stromectol from topical ivermectin formulations, which act locally within the epidermis. Stromectol’s systemic reach is essential for treating infections such as strongyloidiasis, crusted scabies, and resistant lice, where parasites inhabit deeper tissues or circulate through the body.
Together, these pharmacodynamic properties establish Stromectol as a cornerstone therapy for systemic parasitic infections, combining selective neurotoxicity toward parasites with predictable whole‑body distribution.
Stromectol, the branded oral formulation of ivermectin, follows a well‑defined pharmacokinetic profile shaped by its lipophilicity, metabolic pathway, and food‑dependent absorption. After oral administration, Stromectol is absorbed in the gastrointestinal tract, with fat‑rich meals significantly increasing bioavailability. This enhancement occurs because ivermectin dissolves more efficiently in lipid environments, improving uptake and systemic exposure. For a broader overview of PK principles, see Ivermectin PK.
Once absorbed, Stromectol demonstrates extensive distribution due to its strong affinity for lipid‑rich tissues. The drug is highly lipophilic and strongly protein‑bound, allowing it to reach peripheral compartments and maintain prolonged systemic activity. This distribution profile is essential for treating systemic parasitic infections where parasites may reside in deeper tissues or circulate through the bloodstream.
Stromectol undergoes hepatic metabolism primarily via CYP3A4, with additional minor oxidative pathways contributing to biotransformation. Because CYP3A4 plays a central role, co‑administered inhibitors or inducers may influence systemic exposure. The metabolites formed are generally less active and are prepared for biliary elimination.
Excretion occurs mainly through the biliary–fecal route, with minimal renal clearance. The elimination half‑life is prolonged due to strong tissue binding and slow redistribution, supporting single‑dose or interval‑based dosing strategies commonly used in antiparasitic therapy. These PK characteristics explain Stromectol’s effectiveness in systemic infections requiring sustained exposure and deep tissue penetration.
| Parameter | Description |
|---|---|
| Absorption | Enhanced with high‑fat meals; increased systemic bioavailability |
| Distribution | Highly lipophilic; strong protein binding; extensive tissue penetration |
| Metabolism | Primarily via CYP3A4; oxidative hepatic pathways |
| Elimination | Biliary–fecal excretion; long elimination half‑life |
Stromectol, the branded oral formulation of ivermectin, is used for systemic parasitic infections requiring full‑body distribution and predictable pharmacokinetics. As a prescription antiparasitic, it remains a reference standard in clinical guidelines and is frequently selected when high manufacturing consistency and brand‑level assurance are desired. Stromectol’s indications overlap with those of generic ivermectin, but its branded status influences clinical preference in certain settings.
Scabies. Stromectol is widely used for classic, crusted, and treatment‑resistant scabies. Its systemic distribution allows it to target mites and larvae located beyond the skin surface. Stromectol is often chosen when topical therapy fails or when widespread infestation requires systemic treatment. More details: Ivermectin for scabies.
Strongyloidiasis. Stromectol is a first‑line therapy for Strongyloides stercoralis, a systemic nematode infection requiring deep tissue penetration. Its predictable pharmacokinetics and long half‑life make it highly effective for circulating larvae. More information: Ivermectin for strongyloides.
Lice infestations. Stromectol is used for resistant or recurrent lice, especially when topical agents are ineffective or impractical. Its systemic action ensures coverage even when parasites are difficult to reach. More details: Ivermectin for lice.
Although generic ivermectin provides equivalent therapeutic efficacy, Stromectol is selected in several clinical and commercial scenarios:
Brand trust. Stromectol’s long‑standing regulatory history and consistent manufacturing standards make it a preferred option in regions where brand assurance is valued.
Stable dosing and formulation consistency. As a single‑manufacturer product, Stromectol offers uniform excipients and tablet characteristics, which some clinicians prefer for predictable pharmacokinetics.
Clinical guideline alignment. Many historical guidelines reference Stromectol specifically, especially in strongyloidiasis and crusted scabies protocols. While generics are equivalent, Stromectol remains the named standard in several documents.
| Parameter | Stromectol | Generic ivermectin |
|---|---|---|
| Scabies | Used for classic, crusted, resistant cases; strong brand preference | Equivalent efficacy; widely used |
| Strongyloidiasis | Referenced in guidelines; predictable PK | Equivalent therapeutic effect |
| Lice | Preferred when brand assurance is required | Commonly used; cost‑efficient |
| Clinical preference | Brand trust, stable formulation, guideline alignment | Lower cost; broader availability |
Stromectol is supplied as 3 mg and 6 mg oral tablets, allowing clinicians to build weight‑based systemic regimens for parasitic infections. Although Stromectol and generic ivermectin share identical active ingredients, Stromectol is often selected when consistent tablet composition, branded assurance, or guideline‑referenced dosing is preferred. The following information summarizes informational, non‑personalized dosing patterns commonly referenced in antiparasitic therapy. More information: Ivermectin 3 mg, Ivermectin 6 mg.
Form strengths: 3 mg and 6 mg. Stromectol tablets are standardized to these strengths to support flexible weight‑based calculations. The 3 mg tablet is historically the most common, while the 6 mg option allows simplified tablet counts in higher‑weight categories.
Informational dosing schemes. Stromectol is typically administered as a single systemic dose or as part of a structured two‑dose regimen depending on the infection type. These patterns reflect how antiparasitic therapy is commonly organized in clinical guidelines. Interval‑based dosing is frequently used to target parasites at different life‑cycle stages.
Repeat courses. In cases of persistent infestation, high parasite burden, or incomplete response, informational protocols may include repeat courses. These follow predefined intervals and are based on the biological behavior of the parasite rather than individualized adjustments.
High parasite load considerations. In infections with heavy microfilarial or larval burden, Stromectol may trigger stronger inflammatory responses due to rapid parasite death. Informational protocols sometimes incorporate staged or repeated dosing to manage parasite clearance over time. These considerations are mechanistic and reflect how systemic antiparasitic therapy is structured in high‑burden scenarios.
| Condition | Pattern | Interval | Notes |
|---|---|---|---|
| Scabies | Single systemic dose ± repeat | Second dose after a defined interval | Used for classic, crusted, or resistant cases |
| Strongyloidiasis | Weight‑based systemic dose | May include repeat dosing | Targets circulating and tissue‑dwelling larvae |
| Lice | Systemic dose ± repeat | Repeat after a defined interval | Used when topical agents fail or are impractical |
| High parasite load | Staged or repeated informational dosing | Structured intervals | Reflects parasite‑load–dependent responses |
Stromectol, the branded oral formulation of ivermectin, shares the same systemic safety profile as generic ivermectin but is often referenced directly in clinical guidelines due to its long‑standing regulatory status. Understanding its contraindications and precautionary factors is essential for safe use, especially in systemic parasitic infections. A broader overview of safety principles is available in Ivermectin oral — precautions.
Stromectol is generally avoided in individuals with known hypersensitivity to ivermectin or other macrocyclic lactones. Because the drug undergoes hepatic metabolism, significant liver impairment may alter systemic clearance, increasing exposure. Conditions associated with compromised blood–brain barrier integrity—such as certain neurological disorders—may increase the risk of central nervous system penetration, making them a relative contraindication in specific contexts. These considerations apply equally to branded and generic formulations.
Stromectol is metabolized primarily via CYP3A4, making it susceptible to interactions with strong inhibitors (e.g., azole antifungals, macrolides, antiretrovirals) that may elevate systemic ivermectin levels. CYP3A4 inducers may reduce exposure, potentially lowering antiparasitic effectiveness. Stromectol is also a substrate of P‑glycoprotein (P‑gp), and combined inhibition of CYP3A4 and P‑gp can further increase systemic concentrations. These interactions are mechanistic and informational, reflecting how metabolic and transporter pathways influence systemic exposure.
Certain groups require additional caution due to altered pharmacokinetics or increased susceptibility to adverse effects. These include frail older adults, individuals with severe systemic illness, and patients with conditions affecting hepatic metabolism. In endemic regions, individuals with high Loa loa microfilarial loads may experience severe inflammatory reactions due to rapid parasite killing. Pregnant or breastfeeding individuals are typically evaluated carefully because systemic exposure may affect fetal or neonatal development. Although Stromectol and generic ivermectin are therapeutically equivalent, branded formulations may be preferred in populations where consistent excipient profiles are valued.
| Category | Description |
|---|---|
| General contraindications | Hypersensitivity, severe hepatic impairment, compromised blood–brain barrier |
| Drug interactions | CYP3A4 inhibitors/inducers; P‑gp modulators affecting systemic exposure |
| Special populations | Pregnancy, breastfeeding, frail adults, high Loa loa microfilarial burden |
Stromectol, the branded oral formulation of ivermectin, follows the same systemic interaction profile as generic ivermectin but is often referenced directly in clinical guidelines due to its consistent manufacturing standards. Because Stromectol undergoes hepatic metabolism and relies on transporter‑mediated distribution, several interaction categories are clinically relevant. A broader overview is available in Ivermectin oral interactions.
Stromectol is metabolized primarily by CYP3A4, making it sensitive to co‑administered inhibitors and inducers. Strong CYP3A4 inhibitors—such as azole antifungals, macrolide antibiotics, and certain antiretrovirals—may increase systemic ivermectin exposure, potentially intensifying pharmacologic effects. Conversely, CYP3A4 inducers may reduce plasma levels, lowering antiparasitic activity. These interactions reflect the metabolic dependency shared by both branded and generic formulations.
Stromectol is also a substrate of P‑glycoprotein, an efflux transporter that limits drug penetration into sensitive tissues, including the central nervous system. Inhibition of P‑gp (e.g., by certain calcium channel blockers, macrolides, or immunosuppressants) may increase ivermectin distribution and raise the risk of CNS exposure. Combined CYP3A4 and P‑gp inhibition can have an additive effect on systemic levels.
Stromectol may be used alongside other antiparasitic agents such as albendazole or mebendazole in structured treatment protocols. While these combinations can broaden antiparasitic coverage, they may also increase the likelihood of additive gastrointestinal or systemic effects. These interactions are pharmacodynamic rather than metabolic and reflect how combination therapy is organized in high‑burden parasitic infections.
Stromectol does not have a direct pharmacokinetic interaction with alcohol, but concurrent use may intensify overlapping side effects such as dizziness, fatigue, or gastrointestinal discomfort. Alcohol may also indirectly influence hepatic metabolism, which is relevant given Stromectol’s reliance on CYP3A4 pathways.
| Interaction Type | Description |
|---|---|
| CYP3A4 inhibitors | Increase systemic exposure; may enhance pharmacologic effects |
| P‑gp modulators | Alter tissue distribution; may increase CNS penetration |
| Anthelmintics | Potential additive effects in combination protocols |
| Alcohol | May intensify overlapping side effects; informational caution |
Stromectol, the branded oral formulation of ivermectin, shares the same systemic safety profile as generic ivermectin. Most adverse effects are mild and transient, reflecting both the drug’s pharmacologic action and the body’s response to parasite elimination. A broader overview of safety considerations is available in Ivermectin general safety.
Frequently reported reactions include dizziness, headache, fatigue, nausea, abdominal discomfort, and diarrhea. Mild skin reactions such as itching or rash may also occur, often representing the immune system’s response to dying parasites rather than direct drug toxicity. These effects are typically self‑limiting and resolve without intervention. Stromectol’s branded formulation does not significantly alter the frequency or severity of these common reactions compared with generic ivermectin.
Rare but documented adverse events include hypotension, tachycardia, confusion, ataxia, or other neurological symptoms. These reactions are more likely in individuals with impaired blood–brain barrier function or severe systemic illness. Because Stromectol undergoes hepatic metabolism, patients with significant liver impairment may experience increased systemic exposure, potentially elevating the risk of rare adverse effects.
In infections with high parasite burden—particularly those involving microfilariae—patients may experience Mazzotti‑type reactions. These include fever, lymph node swelling, joint pain, intense itching, and inflammatory skin changes. Such reactions are caused by the immune response to rapid parasite death rather than the drug itself. Stromectol and generic ivermectin produce similar parasite‑load–dependent reactions, although Stromectol may be preferred in high‑burden cases due to its consistent formulation and predictable pharmacokinetics.
| Category | Description |
|---|---|
| Common effects | Dizziness, headache, nausea, abdominal discomfort, mild rash |
| Rare effects | Hypotension, tachycardia, neurological symptoms in susceptible individuals |
| Mazzotti‑type reactions | Fever, lymphadenopathy, pruritus, inflammatory response to parasite death |
Stromectol, the original brand‑name oral ivermectin, is frequently compared with generic ivermectin tablets because both contain the same active ingredient and deliver equivalent antiparasitic activity. However, differences in manufacturing standards, pricing, availability, and regulatory positioning influence how each option is used in clinical and commercial settings. A broader overview of the oral formulation is available on Ivermectin oral, and pricing details can be found at Ivermectin price.
Stromectol and generic ivermectin demonstrate identical therapeutic efficacy. Both act on glutamate‑gated chloride channels, causing paralysis and death of parasites. Clinical studies and treatment guidelines consistently confirm that generics match Stromectol in outcomes for scabies, strongyloidiasis, lice, and other systemic parasitic infections. The choice between them is therefore not based on clinical effectiveness but on commercial and regulatory factors.
Both formulations exhibit equivalent oral bioavailability, influenced by lipophilicity, CYP3A4 metabolism, and increased absorption with high‑fat meals. Minor excipient differences between manufacturers do not meaningfully affect systemic exposure. Stromectol is sometimes preferred in settings where consistent excipient profiles and predictable pharmacokinetics are valued, but generics remain fully interchangeable.
The most significant difference is cost. Stromectol carries a brand‑name premium and is often several times more expensive than generic ivermectin. Generics are widely used in clinical practice due to their affordability and identical therapeutic effect. Pricing varies by region, manufacturer, and supply chain stability, but generics consistently remain the cost‑efficient option.
Generic ivermectin is produced by multiple manufacturers and is therefore more widely available globally. Stromectol, produced by a single originator company, may be limited in certain markets or available only through specific distributors. In regions with strong brand preference or strict regulatory frameworks, Stromectol may be more commonly referenced in guidelines, but generics dominate overall availability.
| Parameter | Stromectol | Generic ivermectin |
|---|---|---|
| Effectiveness | Equivalent to generics; brand‑referenced in some guidelines | Equivalent efficacy across indications |
| Bioavailability | Predictable PK; consistent excipients | Equivalent systemic exposure |
| Price | Higher; brand‑name premium | Lower; cost‑efficient |
| Availability | Single manufacturer; limited in some regions | Multiple manufacturers; widely available |
Stromectol, the branded oral formulation of ivermectin, is often compared with other systemic and topical antiparasitic agents. While all these medications target parasitic infections, their mechanisms, tissue penetration, and clinical roles differ significantly. Stromectol’s systemic distribution and predictable pharmacokinetics make it particularly valuable for infections requiring deep‑tissue or whole‑body coverage. Expanded comparisons are available on Ivermectin vs Permethrin, Ivermectin vs Albendazole, and Ivermectin vs Doxycycline.
Permethrin is a topical pyrethroid used for scabies and lice. Unlike Stromectol, it does not provide systemic activity and acts only on the skin surface. Stromectol is preferred for crusted scabies, widespread infestations, or cases resistant to topical therapy. Permethrin remains first‑line for mild, localized scabies.
Albendazole is a systemic benzimidazole effective against intestinal helminths. It disrupts microtubule formation and parasite glucose uptake. Stromectol is superior for strongyloidiasis and ectoparasitic infections, while albendazole is preferred for gastrointestinal helminths. In some protocols, both drugs are used together for synergistic coverage.
Mebendazole is another benzimidazole with strong activity against pinworm, whipworm, and roundworm. Its poor systemic absorption limits its use to intestinal parasites. Stromectol, with its systemic reach, is preferred for tissue‑migrating larvae and ectoparasites.
Doxycycline is a tetracycline antibiotic with antiparasitic activity through suppression of Wolbachia endosymbionts in filarial worms. It is used in long‑course regimens for onchocerciasis and lymphatic filariasis. Stromectol provides rapid parasite clearance, while doxycycline offers long‑term sterilizing effects. They are often complementary rather than interchangeable.
| Drug | Mechanism | Primary Use | Key Difference |
|---|---|---|---|
| Permethrin | Topical sodium‑channel disruption | Scabies, lice | Local action only; Stromectol provides systemic coverage |
| Albendazole | Microtubule inhibition | Intestinal helminths | Albendazole is GI‑focused; Stromectol targets systemic parasites |
| Mebendazole | Microtubule disruption | Pinworm, whipworm, roundworm | Poor systemic absorption; Stromectol reaches tissues |
| Doxycycline | Anti‑Wolbachia antibiotic | Filarial infections | Slow sterilizing effect vs Stromectol’s rapid clearance |
Stromectol, the branded oral formulation of ivermectin, occupies the premium segment of the antiparasitic market. Its cost reflects brand recognition, consistent manufacturing standards, and long‑standing regulatory approval. While both Stromectol and generic ivermectin contain the same active ingredient, their pricing differs substantially. A broader overview of pricing dynamics is available on Stromectol price.
Stromectol is available in 3 mg and 6 mg oral tablets, with the 3 mg strength being the historical standard referenced in many treatment guidelines. The 6 mg version offers simplified tablet counts for higher‑weight dosing. Branded tablets typically cost significantly more than their generic equivalents, with price variation depending on region, pharmacy markup, and distribution channel. In many markets, Stromectol may be several times more expensive than generic ivermectin of the same strength.
Generic ivermectin is widely recognized as the cost‑efficient alternative, produced by multiple manufacturers and benefiting from competitive pricing. Stromectol, by contrast, carries a brand‑name premium, reflecting its originator status and consistent excipient profile. While therapeutic efficacy is identical, the commercial difference is substantial, making generics the preferred option in most clinical and retail settings.
Several variables affect Stromectol’s final retail price: dosage strength, manufacturer exclusivity, regulatory environment, import restrictions, pharmacy markups, and supply chain stability. Market demand and regional availability also contribute to price fluctuations. Because Stromectol is produced by a single originator company, its pricing is more sensitive to distribution and regulatory factors than generic ivermectin.
| Strength | Typical Price Range |
|---|---|
| 3 mg | Higher cost; varies by region and distributor |
| 6 mg | Premium pricing; limited availability in some markets |